NEW YORK--(BUSINESS WIRE)--June 2, 2006--Callisto Pharmaceuticals, Inc. (AMEX:KAL - News; FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today a further update on the clinical data from a Phase I study of the safety and efficacy of Atiprimod, a novel azaspirane, for patients with advanced cancer. The trial, conducted at M.D. Anderson CancerCenter is an ongoing, single-center, open label, ascending dose Phase I trial of oral Atiprimod in patients with advanced cancer. Atiprimod was given by single dose orally for 14 days of every 28-day cycle.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.